Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (PL)

Advances in Clinical and Experimental Medicine

2006, vol. 15, nr 5, September-October, p. 897–903

Publication type: review article

Language: Polish

Hiperhomocysteinemia jako nowy czynnik ryzyka wielu chorób

Hyperhomocysteinemia as a New Risk Factor for Different Diseases

Monika Łubińska1,, Ewa Kazimierska1,, Krzysztof Sworczak1,

1 Klinika Chorób Wewnętrznych, Endokrynologii i Zaburzeń Hemostazy Instytutu Chorób Wewnętrznych AM w Gdańsku

Streszczenie

Prezentowana praca przedstawia aktualne poglądy na temat homocysteiny oraz jej wpływu na powstawanie zmian chorobowych. Opisano metabolizm homocysteiny oraz wpływ różnych czynników na jego przebieg, a także patomechanizm zmian wynikających z hiperhomocysteinemii. Obszernie omówiono znaczenie kliniczne oraz związek zwiększonego stężenia homocysteiny z rozwojem zmian miażdżycowych, choroby zakrzepowo−zatorowej, przewlekłej niewydolności nerek, zaburzeń psychicznych, a także przebiegiem ciąży. Podzielone opinie dotyczące patomechanizmu działania homocysteiny oraz jej istotnego wpływu na rozwój wielu chorób, skłaniają do dalszych badań i rozwiania wątpliwości.

Abstract

The article reviews current events about homocysteine and its effect on morbid changes appearance. The metabolism of homocysteine, an influence of different factors on it and the pathomechanism of associated with hyperhomocysteinemia patologic changes are described. The clinical significance and relationship between elevated plasma homocysteine and atherosclerosis, deep vein thrombosis, chronic renal failure, mental disorders and disturbances during pregnancy are widely discussed. The different opinions on the pathomechanism of homocysteine−dependent effect and its influence on development of many diseases suggest further research.

Słowa kluczowe

homocysteina, hiperhomocysteinemia, miażdżyca, zaburzenia krzepnięcia, depresja

Key words

homocysteine, hyperhomocysteinemia, arteriosclerosis, coagulation disorders, depression

References (43)

  1. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M, DACH – LIGA Homocystein e.V: DACH – LIGA homocystein (German, Austrian, and Swiss homocysteine society) consensus paper on the rational clinical use of homocysteine, folic acid, and B−vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003, 41, 1392–1403.
  2. Clark R, Collins R, Lewington S, Donald A: Homocysteine and risk of ischemic heart disease and stroke: a meta−analysis. JAMA 2002, 288, 2015–2022.
  3. Refsum H, Smith AD, Ueland PM, Nexo E, Clark R, McPartlin J, Johnson C, Engbaek F, Schneede J, McPartlin C, Scott IM: Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion. Clin Chem 2004, 50, 3–32.
  4. Bostom AG, Culleton BF: Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999, 10, 891–900.
  5. Walker MC, Smith GN, Perkins SL, Kelly EJ, Garner PR: Changes in homocysteine levels during normal pregnancy. Am J Obstet Gynecol 1999, 180, 660–664.
  6. De Bree A, Verschuren WM, Blom HJ, Kromhout D: Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 2001, 154, 150–154.
  7. Refsum H, Yjanik CS, Gadkari M, Schneede J, Vollset SE, Orning L, Guttormsen AB, Joglekar A, Sayyad MG, Ulwik A, Ueland PM: Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians. Am J Clin Nutr 2001, 74, 233–241.
  8. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IM: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993, 270, 2693–2698.
  9. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ, Delport R, Potgieter HC: Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994, 124, 1927–1933.
  10. Kazimierska E, Częstochowska E: Stężenie homocysteiny, witaminy B12 i kwasu foliowego w surowicy u chorych z alkoholową chorobą wątroby. Pol Merk Lek 2003, 15, 140–143.
  11. Moustapha A, Gupta A, Robinson K, Arheart K, Jacobson DW, Schreiber MJ, Dennis VW: Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 1999, 55, 1470–1475.
  12. Kutluana U, Simsek I, Akarsu M, Kupelioglu A, Karasu S, Altekin E: Is there a possible relation between atrophic gastritis and premature atherosclerosis? Helicobacter 2005, 10, 623–629.
  13. Lewandowski K: Hyperhomocysteinemia jako czynnik ryzyka rozwoju zmian naczyniowych. Acta Haematol Pol 1998, 29, 157–169.
  14. Van der Put NM, Steegers−Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Huevel LP, Mariman EC, den Heyer M, Rozen R, Bloom HJ: Mutated methylenetetrahydrofolate reductase as risk factor for spina bifida. Lancet 1995, 346, 1070–1071.
  15. Lucock M: Is folic acid the ultimate functional food component for disease prevention? BMJ 2004, 328, 211–214.
  16. Korzets A, Ori Y, Chagnac A, Weinstein T, Herman M, Zevin D, Malachi T, Gafter U: Erythropoetin, folic acid deficiency and hyperhomocysteinemia: is there a possible relationship in chronically hemodialyzed patients? Clin Nephrol 2000, 53, 48–54.
  17. Lilien M, Duran M, Van Hoeck K, Poll−The BT, Schroder C: Hyperhomocysteinemia in children with chronic renal failure. Nephrol Dial Transplant 1999, 14, 366–368.
  18. Litwin M, Abuauba M, Wawer ZT, Grenda R, Pietraszek E: Folate, vitamin B12, and sulfur amino acid levels in patients with renal failure. Pediatr Nephrol 2001, 16, 127–132.
  19. Orzechowska−Pawiłojć A, Lewczuk A, Sworczak K: Wpływ hormonów tarczycy na poziom homocysteiny w aspekcie ryzyka rozwoju zmian miażdżycowych. Endokrynol Pol 2005, 56, 194–202.
  20. Catargi B, Parrot−Roulaud F, Cochet C, Ducassou D, Roger P, Tabarin A: Homocysteine, hypothyroidism, and effect of thyroid hormone replacement. Thyroid 1999, 9, 1163–1166.
  21. Szymczak E., Gajewska J., Laskowska−Klita T: Wybrane niezależne czynniki ryzyka miażdżycy u dzieci jako podstawa wczesnego wykrywania zagrożenia chorobą niedokrwienną serca. Pol Merkuriusz Lek 2001, 61, 56–59.
  22. Nappo F, De RosaN, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B, Giugliano D: Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999, 281, 2113–2118.
  23. Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, Chait BT: Tissue plasminogen activator binding to the annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998, 273, 9987–9993.
  24. Lentz SR: Mechanism of homocysteine−induced atherothrombosis. J Thromb Haemost 2005, 3, 1646–1654.
  25. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta−analysis. BMJ 2002, 325, 1202–1206.
  26. Stampfer MJ, Willett WC: Homocysteine and marginal vitamin deficiency. The importance of adequate vitamin intake. JAMA 1993, 270, 2726–2727.
  27. Vermeulen EG, Stehouwer CD, Twisk JW, van den Berg M, de Jong SC, Mackaay AJ, van Campen CM, Visser FC, Jacobs CA, Bulterjis EJ, Rauwerda JA: Effects of homocysteine−lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo−controlled trial. Lancet 2000, 355, 517–522.
  28. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW: Prospective study of hyperhomocysteinemia as a adverse cardiovascular risk factor in end−stage renal diseaese. Circulation 1998, 97, 138–141.
  29. Den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR: Hyperhomocysteinemia as a risk factor for deep−vein thrombosis. N Engl J Med 1996, 334, 752–762.
  30. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH: Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 2000, 69, 228–232.
  31. Fava M, Borus JS, Alpert JE, Nierenberg MD, Rosenbaum JF, Bottiglieri T: Folate, vitamin B12 and homocysteine in major depressive disorder. Am J Psychiatry 1997, 154, 426–428.
  32. Refsum H, Smith AD: Low vitamin B12 status in confirmed Alzheimer’s disease as revealed by serum holotranscobalamin. J Neurol Neurosurg Psychiatry 2003, 74, 959–961.
  33. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith D: Plasma homocysteine levels, cerebrovascular risk factor, and cerebral white matter changes in patients with Alzheimer disease. Arch Neurol 2002, 59, 787–793.
  34. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB Wilson PW, Wolf PA: Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Eng J Med 2002, 346, 476–483.
  35. Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Jolles J, Clark R, Breteler MM: Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology 2002, 59, 1375–1380.
  36. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH: Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 2002, 159, 1790–1792.
  37. Hogg BB, Tamura T, Johnston KE, Dubard MB, Goldenberg RL: Second trimester plasma homocysteine levels and pregnancy−induced hypertension, preeclampsia, and intrauterine growth restriction. Am J Obstet Gynecol 2000, 183, 805–809.
  38. Cotter AM, Molloy AM, Scott JM, Daly SF: Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Am J Obstet Gynecol 2001, 185, 781–785.
  39. Ronnerberg AG, Goldman MB, Chen D, Aitken IW, Willett WC, Selhub J, Xu X: Preconception folate and vitamin B (6) status and clinical spontaneous abortion in Chinese women. Obstet Gynecol 2002, 100, 107–113.
  40. Wong WY, Eskes TK, Kuijpers−Jagtman AM, Spauwen PH, Steegers EA, Thomas CM, Hamel BC, Blom HJ, Steegers−Theunissen RP: Nonsyndromic orofacial clefts: association with maternal hyperhomocysteinemia. Teratology 1999, 60, 253–257.
  41. Van der Put NM, van Straaten HW, Trijbels FJ, Blom HJ: Folate, homocysteine and neural tube defects: an overview. Exp Biol Med 2001, 226, 243–270.
  42. Rosenblatt DS, Whitehead VM: Cobalamin and folate deficiency: acquired and hereditary disorders in children. Semin Hematol 1999, 36, 19–34.
  43. Monsen BA, Ueland PM: Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to adolescence. Am J Clin Nutr 2003, 78, 7–21.
© Wroclaw Medical University